Neuromod Devices

Neuromod is proud to announce the receipt of Medical Device Single Audit Program (MDSAP) and EU Medical Device Regulation (MDR) certification for the Lenire Tinnitus Treatment Device.

“Neuromod’s commitment to delivering the highest quality of patient care begins with ensuring our quality management systems are best-in-class,” said Dr. Ross O'Neill, Neuromod Founder & CEO. “MDSAP and MDR certification allows Neuromod to continue expanding Lenire's availability in Europe while positioning the company to commercialize Lenire in new geographies such as Australia, Canada, and beyond.”

In one year, Neuromod has achieved MDSAP certification, MDR approval, Health Canada approval, and TGA approval for the ground breaking tinnitus treatment device, Lenire.

You can read the full coverage over on AudiologyOnline.

Neuromod Advance Multiple Regulatory Approvals to Expedite Global Availability of Lenire -Release 29469 Lenire made regulatory history in 2023 by becoming the first and only FDA-approved bimodal neuromodulation tinnitus treatment device.

“We are already seeing successful outcomes that are helping patients manage tinnitus more effectively.”

Did you know more than 65 million adults in Europe live with tinnitus? That’s millions of people searching for relief every single day.

At Neuromod, we’re expanding the availability of across Europe, partnering with leading hearing care professionals to bring life-changing treatment to more patients.

Neuromod Expands Availability of Lenire Tinnitus Treatment Device in Europe with 19 New Clinical Partnerships -Release 29460 Neuromod Devices announced 19 new clinical partnerships to expand the availability of the Lenire tinnitus treatment device in Europe

Lenire Real World Evidence Published in Nature Comms Medicine - Lenire® Lenire Real World Evidence Published. Nature Comms Med has published the 1st analysis of US real world Lenire tinnitus patients.

Happy St. Patrick’s Day to all our friends, family and colleagues from Neuromod Devices.

As an Irish company, today is a special day to celebrate our heritage, innovation, and the global community we’re proud to be part of. Whether you're at home or abroad, we hope your day is filled with joy, luck, and a touch of Irish magic ☘️

Irish Examiner coverage of Neuromod Devices closing €10m financing to further expand availability of Lenire Tinnitus Treatment Device. 2.9 million US Veterans live with tinnitus.

Neuromod is working with U.S. Department of Veterans Affairs and other US Government services to increase Veteran access to Lenire, the only FDA Approved bimodal tinnitus treatment device.

Irish med device expands its tinnitus treatment for US military vets Neuromod has closed a €10m round of equity financing as it looks to expand the availability of its tinnitus treatment device

Neuromod Devices has today announced the company has closed €10m financing to accelerate commercialisation, and availability of Lenire Tinnitus Treatment Device. Financing led by existing investors Fountain Healthcare Partners and Panakes Partners.

“We are delighted to announce an oversubscribed financing at a pivotal time when we are driving forward with our mission of making Neuromod the category creator for tinnitus globally,” said Dr. Ross O’Neill PhD, Founder & CEO of Neuromod.

Neuromod Devices | Neuromod Closes €10m Financing to Accelerate Commercialisation Neuromod Devices is an ambitious, forward-looking medical technology company formed to advance the science of neuromodulation, we named ourselves Neuromod in the shared belief of what this cutting edge branch of medicine can achieve.

Don't miss Session One of the The Tinnitus Collaborative's Virtual Sessions 2024, starting at 4PM (EST) on Tuesday, Oct. 22 — https://shorturl.at/jplWC

Dr. Craig Kasper Au. D. will discussing Bimodal Neuromodulation for Tinnitus: Real-World Clinical Outcomes of Lenire, and Dr. Rachael Cook, Au.D. will dive into Biometric Tracking & Personalized Care of Tinnitus Patients.

Register for The Tinnitus Collaborative Virtual Sessions: Session One for an exciting look at the future of tinnitus care with leading tinnitus experts.

"Expect bimodal neuromodulation to be one of the most popular forms of treatment..."

Check out Doctor Cliff AuD's video about the results of the TENT-A3 controlled clinical trial of Lenire Tinnitus Treatment Device.

TENT-A3's results were pivotal in Lenire becoming the first and only bimodal neuromodulation device approved for the treatment of tinnitus by the US FDA.

Dr. Olson discusses:
- How the TENT-A3 trial was designed and controlled
- The importance of evidence for tinnitus treatment
- The significance of Lenire's benefit for people living with tinnitus

Doctor Cliff AuD Educating consumers about hearing loss and treatment options.

Mark Van Oirschot's Incredible Relief from Chronic Tinnitus Mark Van Oirschot was struggling with severe tinnitus until Lenire gave him relief from chronic tinnitus. Read his inspiring story.